Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Next Previous
Trial Profile

Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Lanifibranor (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Aug 2018 According to an Inventiva Pharma media release, the first of 64 patients for this study has been enrolled in August 2018.
    • 30 Aug 2018 Status changed from not yet recruiting to recruiting, according to an Inventiva Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top